---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-347897"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2026-08-13T11:37:30+00:00"
generated_at: "2026-08-13T11:40:07.437833+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Karyopharm Q2 net loss $67M; cash runway only to Sept 2026, sNDA on track

## Summary
- Q2 2026 total revenue $33.4M (vs $37.9M YoY); U.S. XPOVIO net product revenue $30.8M (vs $29.7M).
- Net loss $67.0M ($2.32/share) vs $37.3M loss ($4.32/share) in Q2 2025; operating loss $22.5M.
- Cash $65.4M at June 30; expects funding only into Sept 2026; $15.8M term loan payment due Sept 10, 2026 may trigger default.
- Planned August sNDA for selinexor+ruxolitinib in myelofibrosis under Accelerated Approval; FDA feedback supports SVR35 as surrogate.
- Phase 3 XPORT-EC-042 endometrial trial missed primary endpoint (PFS); median PFS 12.75 vs 7.43 months, HR 0.76, p=0.0791.

## SEC filing metadata
- accession: 0001193125-26-347897
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2026-08-13T11:37:30+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312526347897/0001193125-26-347897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312526347897/kpti-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-347897
- JSON: https://secwatch.observer/filing/0001193125-26-347897.json
- Plain text: https://secwatch.observer/filing/0001193125-26-347897.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.